United Therapeutics Corp (UTHR) Tops Q2 EPS Views
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $508.48 +1.75%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q2 EPS of $1.49, $0.96 better than the analyst estimate of $0.53. Revenue for the quarter came in at $183.75 million versus the consensus estimate of $180.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics completes enrollment in PPF lung fibrosis trial
- United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
- Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
